Quinolone compounds for the treatment of disorders caused by
helicobacter pylori
    2.
    发明授权
    Quinolone compounds for the treatment of disorders caused by helicobacter pylori 失效
    喹诺酮化合物用于治疗由幽门螺杆菌引起的疾病

    公开(公告)号:US5942619A

    公开(公告)日:1999-08-24

    申请号:US43374

    申请日:1998-04-24

    摘要: This invention provides processes for producing quinolone compounds which comprise cultivating Amycoa sp. FERM BP-4785, and then isolating quinolone compounds from the fermentation broth. The compounds produced by these processes include compounds of formula (I) wherein R.sup.1 is H, R.sup.2 is (a) and R.sup.3 is CH.sub.3 ; R.sup.1 is CH.sub.3, R.sup.2 is (a) and R.sup.3 is CH.sub.3 ; or R.sup.1 is CH.sub.3, R.sup.2 is (b) and R.sup.3 is CH.sub.3 ; and the like. The present invention also relates to a pharmaceutical composition comprising the same, which is useful in the treatment of diseases, disorders and adverse conditions caused by Helicobacter pylori and is particularly useful in the treatment of gastroduodenal disorders, diseases and adverse conditions caused thereby. ##STR1##

    摘要翻译: PCT No.PCT / IB96 / 00670 Sec。 371日期:1998年4月24日 102(e)1998年4月24日PCT PCT 1996年7月11日PCT公布。 出版物WO97 / 12868 日期:1997年04月10日本发明提供了生产喹诺酮化合物的方法,其中包括培养Amycoa sp。 FERM BP-4785,然后从发酵液中分离出喹诺酮化合物。 通过这些方法制备的化合物包括其中R 1是H,R 2是(a)和R 3是CH 3的式(I)化合物; R1是CH3,R2是(a),R3是CH3; 或R 1为CH 3,R 2为(b),R 3为CH 3; 等等。 本发明还涉及含有该组合物的药物组合物,其可用于治疗由幽门螺杆菌引起的疾病,病症和不利条件,并且特别可用于治疗胃十二指肠疾病,疾病和由此引起的不利条件。

    Rapamycin producer
    3.
    发明授权
    Rapamycin producer 失效
    雷帕霉素生产者

    公开(公告)号:US5674732A

    公开(公告)日:1997-10-07

    申请号:US325378

    申请日:1994-10-26

    IPC分类号: C12N1/20

    CPC分类号: C12R1/045

    摘要: The present invention provides a novel culture which belongs to Actinoplanes (Actinoplanes sp. FERM BP-3832). This culture is capable of producing rapamycin more than ten times efficiently than the cultures which have been reported (e.g., Streptomyces hygroscopicus ATCC 29253). The present invention provides a process for the production of rapamycin which comprises cultivating Actinoplanes sp. FERM BP-3832 and thereafter isolating rapamycin from the fermentation mixture.

    摘要翻译: PCT No.PCT / US93 / 01534 Sec。 371日期:1994年10月26日 102(e)日期1994年10月26日PCT 1993年2月26日PCT PCT。 公开号WO93 / 22446 日期:11月11日,11日本发明提供了属于动植物平面(Actinoplanes sp.FERM BP-3832)的新型培养物。 该培养物能够比已报道的培养物(例如,吸水链霉菌ATCC 29253)有效地产生雷帕霉素的十倍以上。 本发明提供了一种雷帕霉素的生产方法,其包括培养飞蓟素sp。 FERM BP-3832,然后从发酵混合物中分离雷帕霉素。

    Macrocyclic lactone compounds and their production process
    4.
    发明授权
    Macrocyclic lactone compounds and their production process 失效
    大环内酯化合物及其生产工艺

    公开(公告)号:US06187568B1

    公开(公告)日:2001-02-13

    申请号:US09378062

    申请日:1999-08-20

    IPC分类号: C12P1718

    CPC分类号: C07D498/18 C12P17/188

    摘要: This invention provides a process for producing a macrocyclic lactone compound, which comprises cultivating Actinoplanes sp. FERM BP-3832, in the presence of L-proline, L-hydroxyproline or L-nipecotic acid, and then isolating a macrocylic lactone compound from the fermentation broth. The compounds produced by this process include a compound of the following formula: The present invention also relates to a pharmaceutical composition comprising the same, which is useful as immunosuppressive, antimycotic, antitumor agent or the like.

    摘要翻译: 本发明提供了一种制备大环内酯化合物的方法,其包括培养活性平板体。 FERM BP-3832,在L-脯氨酸,L-羟脯氨酸或L-乳酸的存在下,然后从发酵液中分离大环内酯化合物。 通过该方法制备的化合物包括下式的化合物:本发明还涉及包含该化合物的药物组合物,其可用作免疫抑制,抗真菌剂,抗肿瘤剂等。